HELLO TO Y'ALL!
I'll write this message in short terms, so all you busy american investors can read it, not losing valuable time, and get THE ONE chance in your lifetime to make a dig for THE REALLY BIG GOLD NUGGET. Especially you americans may think, that the experimental drug candidate, belinostat, is owned alone by an american medical drugcompany. That belinostat is one of more drugs in their portfolio, and therefore only represent a smaller part of this companys common Value. But how wrong can you be, dear fellow americans? As wrong as if you wote a republican for president, perhaps? I would say even more wrong. For the danish bioteque company Topotarget is practically equal to belinostat, which is (also) practically the only drug getting investigated in their portfolio. Belinostat has been called 'best in class' and has been placed on top of lists over drugs with 'blockbustertpotential'. And now the news has begun to drip in, that proves it. So when the good news arrive, it will be the shares of Topotarget that shall jump, as they in a small way already have begun, not their american belinostat-partner with their full portfolio. Recently the marked misunderstood and panicked over some partly good belinostat-news, and therefore the shares of Topotarget dropped and has now become extremely cheap. And that is still the case, in spite of some more recent very good news.
KIND REGARDS TO Y'ALL
Jamesol
I'll write this message in short terms, so all you busy american investors can read it, not losing valuable time, and get THE ONE chance in your lifetime to make a dig for THE REALLY BIG GOLD NUGGET. Especially you americans may think, that the experimental drug candidate, belinostat, is owned alone by an american medical drugcompany. That belinostat is one of more drugs in their portfolio, and therefore only represent a smaller part of this companys common Value. But how wrong can you be, dear fellow americans? As wrong as if you wote a republican for president, perhaps? I would say even more wrong. For the danish bioteque company Topotarget is practically equal to belinostat, which is (also) practically the only drug getting investigated in their portfolio. Belinostat has been called 'best in class' and has been placed on top of lists over drugs with 'blockbustertpotential'. And now the news has begun to drip in, that proves it. So when the good news arrive, it will be the shares of Topotarget that shall jump, as they in a small way already have begun, not their american belinostat-partner with their full portfolio. Recently the marked misunderstood and panicked over some partly good belinostat-news, and therefore the shares of Topotarget dropped and has now become extremely cheap. And that is still the case, in spite of some more recent very good news.
KIND REGARDS TO Y'ALL
Jamesol
